vs
Side-by-side financial comparison of CARVANA CO. (CVNA) and Medtronic (MDT). Click either name above to swap in a different company.
Medtronic is the larger business by last-quarter revenue ($9.0B vs $4.2B, roughly 2.1× CARVANA CO.). Medtronic runs the higher net margin — 12.8% vs 8.8%, a 3.9% gap on every dollar of revenue. On growth, Medtronic posted the faster year-over-year revenue change (8.7% vs -34.2%). Over the past eight quarters, CARVANA CO.'s revenue compounded faster (11.4% CAGR vs 2.5%).
Carvana Co. is an online used car retailer based in Tempe, Arizona. Carvana was named to the 2021 Fortune 500 list, one of the youngest companies to be added to the list.
Medtronic plc is an Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
CVNA vs MDT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.2B | $9.0B |
| Net Profit | $373.0M | $1.1B |
| Gross Margin | — | — |
| Operating Margin | 9.3% | 16.2% |
| Net Margin | 8.8% | 12.8% |
| Revenue YoY | -34.2% | 8.7% |
| Net Profit YoY | -7.9% | -11.7% |
| EPS (diluted) | — | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.2B | $9.0B | ||
| Q4 25 | $5.6B | $9.0B | ||
| Q3 25 | $5.6B | $8.6B | ||
| Q2 25 | $4.8B | $8.9B | ||
| Q1 25 | $4.2B | $8.3B | ||
| Q4 24 | $3.5B | $8.4B | ||
| Q3 24 | $3.7B | $7.9B | ||
| Q2 24 | $3.4B | $8.6B |
| Q1 26 | $373.0M | $1.1B | ||
| Q4 25 | $857.0M | $1.4B | ||
| Q3 25 | $151.0M | $1.0B | ||
| Q2 25 | $183.0M | $1.1B | ||
| Q1 25 | $216.0M | $1.3B | ||
| Q4 24 | $79.0M | $1.3B | ||
| Q3 24 | $85.0M | $1.0B | ||
| Q2 24 | $18.0M | $654.0M |
| Q1 26 | — | — | ||
| Q4 25 | 18.8% | 65.8% | ||
| Q3 25 | 20.3% | 65.0% | ||
| Q2 25 | 22.0% | 64.8% | ||
| Q1 25 | 22.0% | 66.5% | ||
| Q4 24 | 21.5% | 64.9% | ||
| Q3 24 | 22.1% | 65.1% | ||
| Q2 24 | 21.0% | 64.5% |
| Q1 26 | 9.3% | 16.2% | ||
| Q4 25 | 7.6% | 18.8% | ||
| Q3 25 | 9.8% | 16.8% | ||
| Q2 25 | 10.6% | 16.1% | ||
| Q1 25 | 9.3% | 19.9% | ||
| Q4 24 | 7.3% | 19.0% | ||
| Q3 24 | 9.2% | 16.1% | ||
| Q2 24 | 7.6% | 12.3% |
| Q1 26 | 8.8% | 12.8% | ||
| Q4 25 | 15.3% | 15.3% | ||
| Q3 25 | 2.7% | 12.1% | ||
| Q2 25 | 3.8% | 11.8% | ||
| Q1 25 | 5.1% | 15.6% | ||
| Q4 24 | 2.2% | 15.1% | ||
| Q3 24 | 2.3% | 13.2% | ||
| Q2 24 | 0.5% | 7.6% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | — | $1.07 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.81 | ||
| Q1 25 | — | $1.01 | ||
| Q4 24 | — | $0.99 | ||
| Q3 24 | — | $0.80 | ||
| Q2 24 | — | $0.50 |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $4.8B |
| Free Cash FlowOCF − Capex | — | $3.3B |
| FCF MarginFCF / Revenue | — | 37.1% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 4.14× |
| TTM Free Cash FlowTrailing 4 quarters | — | $6.5B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.8B | ||
| Q4 25 | $430.0M | $925.0M | ||
| Q3 25 | $345.0M | $1.1B | ||
| Q2 25 | $29.0M | $2.5B | ||
| Q1 25 | $232.0M | $2.6B | ||
| Q4 24 | $60.0M | $958.0M | ||
| Q3 24 | $403.0M | $986.0M | ||
| Q2 24 | $354.0M | $2.8B |
| Q1 26 | — | $3.3B | ||
| Q4 25 | $379.0M | $457.0M | ||
| Q3 25 | $307.0M | $584.0M | ||
| Q2 25 | $-2.0M | $2.1B | ||
| Q1 25 | $205.0M | $2.1B | ||
| Q4 24 | $36.0M | $554.0M | ||
| Q3 24 | $376.0M | $466.0M | ||
| Q2 24 | $332.0M | $2.4B |
| Q1 26 | — | 37.1% | ||
| Q4 25 | 6.8% | 5.1% | ||
| Q3 25 | 5.4% | 6.8% | ||
| Q2 25 | -0.0% | 23.2% | ||
| Q1 25 | 4.8% | 25.3% | ||
| Q4 24 | 1.0% | 6.6% | ||
| Q3 24 | 10.3% | 5.9% | ||
| Q2 24 | 9.7% | 27.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 5.2% | ||
| Q3 25 | 0.7% | 5.9% | ||
| Q2 25 | 0.6% | 5.1% | ||
| Q1 25 | 0.6% | 5.7% | ||
| Q4 24 | 0.7% | 4.8% | ||
| Q3 24 | 0.7% | 6.6% | ||
| Q2 24 | 0.6% | 5.0% |
| Q1 26 | — | 4.14× | ||
| Q4 25 | 0.50× | 0.67× | ||
| Q3 25 | 2.28× | 1.05× | ||
| Q2 25 | 0.16× | 2.39× | ||
| Q1 25 | 1.07× | 1.99× | ||
| Q4 24 | 0.76× | 0.75× | ||
| Q3 24 | 4.74× | 0.95× | ||
| Q2 24 | 19.67× | 4.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVNA
Segment breakdown not available.
MDT
| Cardiovascular Portfolio | $3.5B | 38% |
| Neuroscience Portfolio | $2.6B | 28% |
| Medical Surgical Portfolio | $2.2B | 24% |
| Diabetes business | $796.0M | 9% |
